Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The impact of polymorphisms in the genes coding for angiotensinogen (M235T), ACE (ID), and angiotensin II type 1 receptor (A(1166)-->C) on decline in GFR and doubling of s-creatinine or development of ESRD in patients with type 1 diabetes and diabetic nephropathy (DN) was tested.
|
14569094 |
2003 |
Diabetic Nephropathy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Ameliorative potential of angiotensin1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats.
|
20383342 |
2010 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that neither the M235T nor the T174M polymorphism in the angiotensinogen gene contributes to genetic susceptibility to diabetic nephropathy in white IDDM patients, whereas the TT genotype of the M235T is associated with elevated blood pressure in patients with diabetic nephropathy.
|
8593944 |
1996 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effects of some RAAS gene variants, including angiotensin converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R), on the risk for DN have been studied more extensively, but there has been controversy.
|
26619914 |
2016 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neither the AGT TT genotype nor the T allele were associated with the progression of DN in either sex after adjusting for confounding factors.
|
18849600 |
2009 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ET-1 and AngII were also significantly decreased in three treatment groups (p < 0.01 vs. the DKD group), especially in the P + A group.
|
29185789 |
2018 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphism M235T in the angiotensinogen gene, which is associated with higher expression of this gene, contributes to the risk of diabetic nephropathy in NIDDM men but not in women.
|
9535411 |
1998 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A substitution (M235T) polymorphism in angiotensinogen (AGT) may interact with ACE I/D polymorphism for the risk of diabetic nephropathy, but their prognostic values have to be established by follow-up studies.
|
11181802 |
2001 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The widely studied candidate genes of the renin-angiotensin-aldosterone system, angiotensinogen (AGT), and angiotensin II receptor type 1 (AGTR1), are implicated in the development of diabetic nephropathy (DN).
|
21607620 |
2012 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that increasing AcSDKP by blocking the ACE N-domain facilitates sodium excretion and ameliorates diabetic kidney disease independent of intrarenal angiotensin II regulation.
|
30185469 |
2018 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic frequencies of the ACE-D and AGT-235T alleles were similar between patients with and without nephropathy in either type of diabetes, and accordingly, there was no significant association between diabetic nephropathy and the ACE or AGT genotype.
|
9049480 |
1997 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 102 individuals were screened for the presence of the ACE I/D and AGT M235T polymorphism: 46 individuals who had type 2 DM with diabetic nephropathy and, as controls, 56 individuals who had type 2 DM without diabetic nephropathy.
|
18413162 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, normalizing testosterone and inhibiting renal angiotensin II have a renoprotective effect against DN in HG male rats.
|
30970225 |
2019 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gene-gene interaction between acetyl-coenzymeA carboxylase beta (ACACβ) gene, which is involved in fatty acid metabolism and angiotensin II receptors (AGTR1) gene, which mediates RAS proteins actions on renal tissue, polymorphism with DN have not been studied earlier.
|
23081748 |
2013 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.
|
12663475 |
2003 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study has shown that AGT M235T TT genotype and APO E ε 2/3 genotype may be linked to a risk for DN among Turkish population.
|
21500980 |
2011 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the role of the renin-angiotensin system (RAS) in diabetic nephropathy, we examined the association between diabetic nephropathy in a large cohort of Japanese type 2 diabetic patients and polymorphisms within the genes that encode angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II receptor type 1 (AGTR1).
|
17143591 |
2007 |
Diabetic Nephropathy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats.
|
17890855 |
2008 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g).
|
28468961 |
2017 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although the renin-angiotensin system has been implicated in the pathogenesis of diabetic nephropathy, angiotensin I-converting enzyme inhibitors have a beneficial effect on diabetic nephropathy independently of their effects on blood pressure and plasma angiotensin II levels.
|
22318421 |
2012 |
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggested that ACE I/D polymorphism, but not AGN M235T polymorphism, is a possible genetic risk factor for diabetic nephropathy in Japanese NIDDM patients.
|
8596493 |
1996 |
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This risk could be attributed to the increasing activity of ACE and angiotensin II level in the presence of D allele and decreasing NO production in the presence of T allele accelerating diabetic nephropathy.
|
22026967 |
2012 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors.
|
15031673 |
2004 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The anti-DN benefit of vitamin D can be enhanced when administrated in combination with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
|
30287151 |
2019 |
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the diabetic milieu per se , hemodynamic changes, oxidative stress and local growth factors such as angiotensin II (AII) are considered to be mediators in the pathogenesis of diabetic nephropathy, the underlying pathways mediating the changes in glomerular endothelial cells (GECs) are not well understood.
|
27358275 |
2017 |